Liraglutide vs Survodutide
Both Liraglutide and Survodutide are used for weight-loss and metabolic. Here's how their evidence, dosing, and regulatory status actually compare.
Liraglutide
Evidence A+Liraglutide (Saxenda / Victoza)
The original once-daily GLP-1 receptor agonist. Lower weight-loss magnitude than semaglutide but a longer real-world track record across diabetes and obesity.
View full Liraglutide profile →Survodutide
Evidence ASurvodutide (BI 456906)
A dual GLP-1 / glucagon receptor agonist with strong Phase 2 weight-loss and MASH data. Resolution of MASH in 83% of participants at the highest dose at week 48.
View full Survodutide profile →Side-by-Side
| Attribute | Liraglutide | Survodutide |
|---|---|---|
| Evidence Grade | A+ | A |
| FDA Status | FDA-approved for weight management (Saxenda) and type 2 diabetes (Victoza) | Not FDA-approved — Phase 3 trials for obesity and MASH |
| Typical Dose | 0.6–3.0 mg daily (subcutaneous) | Trial range: 0.6–6 mg weekly (subcutaneous) |
| Clinics Indexed | 540 | 6 |
| Categories | weight-loss, metabolic | weight-loss, metabolic |
Key reported benefits — Liraglutide
- ✓Weight loss
- ✓Appetite suppression
- ✓Glycemic control
Key reported benefits — Survodutide
- ✓Weight loss
- ✓MASH resolution
- ✓Glucose control
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.